

a neutral phospholipid, 20 to 40 mol % of cholesterol and 5 to 10 mol % of a negatively charged phospholipid.

23. The composition according to Claim 22 wherein the α -interferon B/D hybrid is a α -interferon BDBB hybrid.

24. The composition according to Claim 22 wherein the neutral phospholipid component comprises at least one phosphatidylcholines.

25. The composition according to Claim 22 wherein the neutral phospholipid component is dimyristoyl phosphatidylcholine or a mixture of dimyristoyl phosphatidylcholine with another neutral phosphatidylcholine.

26. The composition according to Claim 22 wherein the negatively charged phospholipid component comprises at least one phosphatidylserine.

27. The composition according to Claim 22 wherein the negatively charged phospholipid component is dioleoyl phosphatidylserine.

28. The composition according to Claim 22 wherein the lipid mixture comprises 55 to 70 mol % neutral phospholipid, 25 to 36 mol % cholesterol and 5 to 10 mol % negatively charged phospholipid.

29. The composition according to Claim 22 wherein the molar ratio of neutral phospholipid: cholesterol: charged phospholipid is 9:5:1.

30. The composition according to Claim 22 wherein the liposomes have an average particle size up to 200 nanometers.

31. The composition according to Claim 30 wherein the liposomes have an average particle size of 80 to 180 nm.

32. The composition according to Claim 22 wherein the weight ratio of the α -interferon B/D hybrid to the lipid mixture is from 1:400 to 1:300.

1000155-102401
A2 cont